Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ) just unveiled an announcement.
Infant Bacterial Therapeutics AB announced that the results from their pivotal Phase III trial, The Connection Study, will be presented at the ESPGHAN 2025 conference in Helsinki. The study evaluates the efficacy of IBP-9414, a product designed to prevent NEC in preterm infants, and its findings could significantly impact the treatment of this life-threatening condition, potentially enhancing IBT’s position in the pediatric biotherapeutics market.
More about Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) operates in the biopharmaceutical industry, focusing on developing treatments for diseases affecting infants. Their primary product, IBP-9414, is a Live Biotherapeutic Product aimed at preventing necrotizing enterocolitis (NEC) and reducing mortality in preterm infants.
Average Trading Volume: 20,902
Current Market Cap: SEK788.1M
Learn more about IBT.B stock on TipRanks’ Stock Analysis page.